These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 18178273)

  • 1. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
    Goode KM; Clark AL; Cleland JG
    Int J Cardiol; 2008 Nov; 130(3):426-37. PubMed ID: 18178273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care.
    Verdú JM; Comín-Colet J; Domingo M; Lupón J; Gómez M; Molina L; Casacuberta JM; Muñoz MA; Mena A; Bruguera-Cortada J
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):613-9. PubMed ID: 22541282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
    Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
    Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.
    Rutten JH; Steyerberg EW; Boomsma F; van Saase JL; Deckers JW; Hoogsteden HC; Lindemans J; van den Meiracker AH
    Am Heart J; 2008 Jul; 156(1):71-7. PubMed ID: 18585499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema.
    Behnes M; Brueckmann M; Ahmad-Nejad P; Lang S; Wolpert C; Elmas E; Kaelsch T; Gruettner J; Weiss C; Borggrefe M; Neumaier M
    Int J Cardiol; 2009 Jun; 135(2):165-74. PubMed ID: 18603317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
    de Lemos JA; McGuire DK; Khera A; Das SR; Murphy SA; Omland T; Drazner MH
    Am Heart J; 2009 Apr; 157(4):746-53.e2. PubMed ID: 19332205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients.
    Romano S; Necozione S; Guarracini L; Fratini S; Cisternino P; di Orio F; Penco M
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):238-44. PubMed ID: 19262210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
    Lam CS; Burnett JC; Costello-Boerrigter L; Rodeheffer RJ; Redfield MM
    J Am Coll Cardiol; 2007 Mar; 49(11):1193-202. PubMed ID: 17367664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms.
    Januzzi JL; Chen-Tournoux AA; Moe G
    Am J Cardiol; 2008 Feb; 101(3A):29-38. PubMed ID: 18243855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurohormonal activation and diagnostic value of cardiac peptides in patients with suspected mild heart failure.
    Mikkelsen KV; Bie P; Møller JE; Videbaek L; Villadsen HD; Haghfelt T
    Int J Cardiol; 2006 Jun; 110(3):324-33. PubMed ID: 16213609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
    Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
    Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.
    Ng LL; Pathik B; Loke IW; Squire IB; Davies JE
    Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NT-proBNP as a means of triage for the risk of hospitalisation in primary care.
    Adlbrecht C; Neuhold S; Hülsmann M; Strunk G; Ehmsen U; Scholten C; Maurer G; Pacher R
    Eur J Prev Cardiol; 2012 Feb; 19(1):55-61. PubMed ID: 21450621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies.
    McDonagh TA; Holmer S; Raymond I; Luchner A; Hildebrant P; Dargie HJ
    Eur J Heart Fail; 2004 Mar; 6(3):269-73. PubMed ID: 14987575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study.
    Moe GW; Howlett J; Januzzi JL; Zowall H;
    Circulation; 2007 Jun; 115(24):3103-10. PubMed ID: 17548729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.